June 10, 2020 / 8:46 AM / 22 days ago

Potential COVID-19 vaccine from China shows promise in animal tests

FILE PHOTO: Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe are seen in this illustration taken taken April 10, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

BEIJING (Reuters) - A potential COVID-19 vaccine being developed by Chinese researchers showed promise in trials in monkeys, triggering antibodies and raising no safety issues, researchers said, and a human trial with more than 1,000 participants is under way.

The vaccine candidate, called BBIBP-CorV, induced high-level neutralising antibodies that can block the virus from infecting cells in monkeys, rats, guinea pigs and rabbits, researchers said in a paper published in online by the medical journal Cell on Saturday.

“These results support the further evaluation of BBIBP-CorV in a clinical trial,” researchers said in the paper. 

BBIBP-CorV, developed by Beijing Institute of Biological Products affiliated to state-owned China National Pharmaceutical Group (Sinopharm), is among five candidates China is testing in humans.

More than 100 potential COVID-19 vaccines are in various stages of development around the world. Among front runners currently in human trials are being developed by AstraZeneca (AZN.L), Pfizer (PFE.N), BioNtech (22UAy.F), Johnson & Johnson (JNJ.N), Merck (MRK.N), Moderna (MRNA.O), Sanofi (SASY.PA) and China’s CanSino Biologics.

As well as appearing safe and able to generate an immune response in animals, BBIBP-CorV did not appear to trigger antibodies that could boost the infection - a phenomenon known as antibody-dependent enhancement (ADE)- the researchers said, although this does not necessarily guarantee ADE won’t occur in human tests.

Apart from BBIBP-CorV, Sinopharm, which has invested 1 billion yuan ($141.40 million) in vaccine projects, is testing in humans another vaccine candidate developed by its Wuhan-based unit. The two shots have been given to more than 2,000 people in clinical trials.

Reporting by Roxanne Liu and Tony Munroe; Editing by Kate Kelland and Nick Macfie

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below